Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982471 | 1.00 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL19778885 | 0.87 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL20938260 | 0.77 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL13190876 | 0.77 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL13494925 | 0.77 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL23742937 | 0.77 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL19418533 | 0.77 | CA1 (0.35) | CA1CA2CA9 | |
| SCHEMBL20169089 | 0.76 | CA1 (0.30) | CA1CA2CA9 | |
| SCHEMBL8004465 | 0.75 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL20367413 | 0.73 | CA2 (0.38) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217577-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| WO-2010028190-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | CA1 958/4885CA2 1158/4885CA9 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.